Loading...
•
Dec 31, 2019
CRISPR Therapeutics Q4 2019 Earnings Report
CRISPR Therapeutics reported financial results, highlighting revenue growth and clinical trial advancements.
Key Takeaways
CRISPR Therapeutics reported a net income of $30.5 million for the fourth quarter of 2019, a significant improvement compared to a net loss of $47.6 million for the same period in 2018. Total collaboration revenue was $77.0 million, driven by collaboration agreements with Vertex. The company's cash and cash equivalents reached $943.8 million.
Reported positive interim data from CTX001 clinical trials for beta thalassemia and sickle cell disease.
Continued enrollment in CTX110 clinical trial targeting CD19+ malignancies.
Began enrollment in CTX120 clinical trial targeting BCMA for multiple myeloma.
Announced Q4 2019 collaboration revenue of $77.0 million, driven by Vertex agreements.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
CRISPR Therapeutics anticipates conducting clinical trials in five indications and expects new data from its immuno-oncology and hemoglobinopathies programs in 2020.
Positive Outlook
- Continued enrollment in clinical trials of CTX001 for severe hemoglobinopathies.
- Ongoing clinical trial of CTX110 targeting CD19+ malignancies.
- Started enrollment in clinical trial of CTX120 targeting BCMA.
- Advancing additional allogeneic CAR-T candidates toward clinical development, including CTX130.
- Expects new data from immuno-oncology and hemoglobinopathies programs.